CRISPR vs. Gene Therapy Round 1: What Investors Need to Know
There’s still a long way to go, but the newcomer is off to a good start.
Bluebird Bio
BLUE
BLUE
$79.42
-$1.23
-1.5%
BATS BZX Real Time Price as of December 6, 2019, 4:00 p.m. EST
View Interactive BLUE Charts
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
News & Analysis: Bluebird Bio
The Fool has written over 200 articles on Bluebird Bio.
Here's Why bluebird bio Fell 21.3% in August
Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.
bluebird bio Prepares for Launch
Zynteglo was recently approved in Europe.
Is bluebird bio a Buy?
Will this bluebird ever bring happiness to its shareholders?
Where Will bluebird bio Be in 1 Year?
The short answer: in great shape.
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
Top 5 Stocks in the Fight Against Cancer
These stocks are leading the way in their respective areas in battling cancer.
It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
bluebird bio Flies Forward
An approval for Zynteglo is imminent.
